SIRNAOMICS-B (02257) establishes an external scientific advisory committee.
Shengno Medicine-B (02257) announced that on July 21, 2026, the company established an External Scientific Advisory Committee (Scientific Advisory Committee) to provide independent, authoritative scientific guidance for the research and development projects of the group's treatment pipeline. The Scientific Advisory Committee consists of five internationally renowned interdisciplinary experts, who have deep expertise in RNA delivery technology, RNAi drug discovery, oncology research and development, clinical translational medicine, chemistry, manufacturing and control (CMC) activities, and global drug regulatory compliance.
SIRNAOMICS-B(02257) announced that on July 21, 2026, the company established an External Scientific Advisory Committee (Scientific Advisory Committee) to provide independent and authoritative scientific guidance for the therapeutic pipeline research and development projects of the group. The Scientific Advisory Committee consists of five internationally renowned interdisciplinary experts with deep expertise in RNA delivery technology, RNAi drug discovery, oncology research and development, clinical translational medicine, chemistry, manufacturing and controls (CMC), and global pharmaceutical regulatory compliance.
Related Articles
US Stock Market Move | Tesla, Inc. (TSLA.US) rises more than 3%, the market expects a year-on-year increase of nearly 30% in Q2 earnings per share.
SUNHO BIO-B(02898): Fan Rongkui terminates his appointment as non-executive director.
CARRY WEALTH (00643): Chen Huiying appointed as executive director.
US Stock Market Move | Tesla, Inc. (TSLA.US) rises more than 3%, the market expects a year-on-year increase of nearly 30% in Q2 earnings per share.
SUNHO BIO-B(02898): Fan Rongkui terminates his appointment as non-executive director.
CARRY WEALTH (00643): Chen Huiying appointed as executive director.
RECOMMEND
